Filter Results:
(610)
Show Results For
- All HBS Web
(610)
- People (4)
- News (110)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Show Results For
- All HBS Web
(610)
- People (4)
- News (110)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
- 08 Aug 2011
- Research & Ideas
The Death of the Global Manager
that are part of operating in today's world." Envisioning The Future Bartlett describes Transnational Management as being in a constant state of evolution. The most recently added chapter, "The Future of the Transnational," includes a case study on the... View Details
Keywords: by Julia Hanna
- 22 Nov 2004
- Research & Ideas
Side Effects: The Case of Propecia
"staggering" 90 percent brand awareness, she said. The problem: some of that awareness was driven by the much-publicized side effects issue. It was difficult for the drug maker to convey the true risk information necessary to blunt the side effects buzz. The... View Details
- 07 Feb 2012
- First Look
First Look: February 7
company can justify the expense of assembling records. The Internet has transformed how economists interact with these datasets by lowering the cost of storing, updating, distributing, finding, and retrieving this information. Second,... View Details
Keywords: Sean Silverthorne
- February 2005 (Revised April 2006)
- Case
Rx Depot: Importing Drugs from Canada
By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot... View Details
Keywords: Courts and Trials; Entrepreneurship; Intellectual Property; Laws and Statutes; Pharmaceutical Industry; Canada; United States
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
- 01 Oct 2021
- News
From Scholarship to Life-Saving Impact
ending up with huge medical bills we couldn’t pay.” Inspired by this personal experience, Rabah chose to build a career in health care. She studied biology as an undergraduate at Cornell, where she developed a strong interest in drug pricing and View Details
- 31 Jan 2014
- News
Body, Heal Thyself
BANCEL Throughout 2009 and 2010, Stéphane Bancel (MBA 2000) had received upward of 20 calls from biotech companies asking him to come aboard and lead the company. It made sense. He was a highly recruited CEO successfully running... View Details
- Web
General Management Awards & Honors - Faculty & Research
advisor to Governors and other public officials on economic issues. Rosabeth M. Kanter : Won the second place 2011 McKinsey Award for the best article in Harvard Business Review during 2010 for “How Great Companies Think Differently.”... View Details
- 05 Aug 2014
- First Look
First Look: August 5
universities and private companies to develop technologies important to Danish industry. We assess the effect of a unique mediated funding scheme that combines project grants with active facilitation and conflict management on firm... View Details
Keywords: Sean Silverthorne
- 15 Dec 2003
- Research & Ideas
The New Global Business Manager
The other is free. Through Project Hope, they seek out people who are suffering from this disease, in Africa or China, for example, and provide the therapy. This approach is in stark contrast to some of the big pharmaceutical View Details
Keywords: by Cynthia Churchwell
- 22 Aug 2005
- Research & Ideas
The Hard Work of Failure Analysis
the hospital quickly followed their example, finding the idea compelling and practical. In the pharmaceutical industry, about 90 percent of newly developed drugs fail in the experimental stage, and thus drug View Details
Keywords: by Amy Edmondson & Mark D. Cannon
- October 2024
- Case
Parexel: Scaling Up and Industry Dynamics
By: Regina E. Herzlinger and Ben Creo
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details
- December 2019
- Supplement
The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)
By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders.
In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details
Keywords: Opioids; Addiction; Business and Stakeholder Relations; Product Launch; Ethics; Society; Pharmaceutical Industry
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids (B)." Harvard Business School Supplement 720-423, December 2019.
- 23 Mar 2010
- First Look
First Look: March 23
catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of side effects, with the... View Details
Keywords: Martha Lagace
- 28 Apr 2009
- First Look
First Look: April 28, 2009
tilted towards old age than annuities. Several advantages of this are discussed, including some that may explain why tontines have proven popular with consumers in the past. Download the paper: http://www.hbs.edu/research/pdf/09-121.pdf PublicationsWhere Is the... View Details
Keywords: Martha Lagace
- 01 Oct 2001
- News
Guy de Chazal: Changing Focus
putting too much faith in innovative companies with exciting ideas but untried management. "At Morgan Stanley, we're back to basics: We look for young companies that have the advantage of entering a... View Details
Keywords: Deborah Blagg
- 13 Oct 2009
- Research & Ideas
7 Lessons for Navigating the Storm
Authentic Leadership. "Everyone inside and outside the company is watching what they do. It is imperative that they stay focused on their True North as it sets a standard internally for principled business behavior and will make... View Details
Keywords: by Martha Lagace
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details
Keywords: Digital Technologies; Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Information Technology; Technology Adoption; Pharmaceutical Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry
Myers, Kyle, and Scott Sawaya. "Myeloma Investment Fund." Harvard Business School Case 625-047, September 2024.
- 10 Aug 2015
- Research & Ideas
New Medical Devices Get To Patients Too Slowly
While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market, the opposite seems to have occurred in the agency's approval of medical devices. Instead of... View Details
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.